Turn­ing can­cer in­to a cur­able dis­ease: Im­munother­a­py ex­pert John Con­nol­ly picks up the reins as the new CSO of Sean Park­er’s can­cer in­sti­tute

John Con­nol­ly synced with the folks at the Park­er In­sti­tute for Can­cer Im­munother­a­py ear­ly on.

As the sci­ence chief at Sin­ga­pore-based Tes­sa Ther­a­peu­tics, he worked on a next-gen CAR-T with an amped up pack­age of T cells. But the same im­munother­a­py fo­cus runs right through his days teach­ing at Bay­lor and on back to get­ting his PhD in im­munol­o­gy from Dart­mouth Med­ical School, where he stud­ied hu­man den­drit­ic cell bi­ol­o­gy, all of which helped make him an ob­vi­ous choice as a top col­lab­o­ra­tor with the in­sti­tute.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER